NNMTi, administered via subcutaneous injection at doses of 5 mg/kg and 10 mg/kg for two weeks (1 week pre-injury and 1 week post-injury), enhances muscle regeneration following injury. It leads to a 60% and 75% higher incidence of proliferating/active muscle stem cells (muSCs) at doses of 5 mg/kg and 10 mg/kg, respectively. The proportion of fibers with an EdU⁺ myonucleus increased by 40% and 48% under NNMTi treatment at 5 mg/kg and 10 mg/kg, respectively. The odds ratio of fused myonuclei for control is 0.58 and 0.53 times the odds at the lower and higher NNMTi doses, respectively^[2].

NNMTi (subcutaneous injection; 10 mg/kg; 1 week) shows no systemic toxicity in mice. There are no significant differences in glucose, cholesterol, plasma proteins, and electrolytes between control and NNMTi-treated mice. Additionally, daily repeat dosing of NNMTi for one week post-injury is well tolerated, with no adverse systemic toxicity or behavioral effects in aged mice^[2].

NNMTi (10-30 μM; 96 hours) induces a dose-dependent increase in myoblast differentiation in C2C12 cells. At 30 μM, NNMTi leads to 18% MHC-positive myotube nuclei, reflecting a 45% enhancement in myoblast differentiation compared to untreated differentiating myoblasts, which show 12% MHC-positive myotube nuclei^[1].